相关实验视频

Updated: Jan 7, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

通过小分子重新激活突变p53的方法治疗乳腺癌

Simon H Slight¹, Salman M Hyder¹

¹Department of Pathobiology and Integrative Biomedical Sciences, University of Missouri, Columbia, MO 65211, USA.

Current oncology (Toronto, Ont.)

|December 24, 2025

概括

用像PRIMA-1和APR-246这样的小分子重新激活突变p53 (mtp53) 在对抗乳腺癌,特别是三阴性乳腺癌 (TNBC) 中表现有前途. 这些化合物恢复野生型p53瘤抑制活性,抑制瘤生长.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症遗传学癌症遗传学

背景情况:

蛋白质p53是一种关键的瘤抑制剂,参与DNA稳定性和亡.
在许多癌症中,p53的突变很常见,包括30%-40%的乳腺癌和70%-80%的三阴性乳腺癌 (TNBC).
突变p53 (mtp53) 积累驱动瘤的发展,使其重新激活成为潜在的治疗策略.

研究的目的:

研究小分子激活剂在乳腺癌中恢复mtp53的功能潜力.
评估PRIMA-1及其同类APR-246在乳腺癌的临床前模型中的疗效,包括TNBC.

主要方法:

利用小分子PRIMA-1和APR-246来准并重新激活mtp53.
在荷尔蒙依赖的人类乳腺癌细胞和TNBC细胞中测试了化合物的疗效.
使用动物异种移植模型评估瘤生长抑制.

主要成果:

PRIMA-1 证明了在荷尔蒙依赖的乳腺癌细胞中重新激活mtp53的能力.
在临床前的异种移植模型中,PRIMA-1有效地阻止了瘤生长.
在TNBC细胞中,APR-246成功地恢复了野生型p53瘤抑制活性.

结论:

小分子激活剂通过恢复p53功能来对抗乳腺癌是一种有希望的方法.
对PRIMA-1和APR-246等化合物的进一步研究,包括自然存在的化合物,可能会导致新的TNBC治疗方法.
临床试验正在探索p53的重新激活作为癌症治疗.

关键词:

普里马1是什么意思?乳腺癌乳腺癌乳腺癌在p53中,p53是什么?再激活重新激活的方法

更多相关视频

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...